WuXi Biologics stock last traded at EUR 5.42 on October 16, 2026 with a P/ E of 34.45

Published on 10/17/2026 at 20:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

WuXi Biologics grew first-half revenue 18.40 percent to CNY 11.787 billion. WuXi Biologics stock last traded at EUR 5.42 on October 16, 2026.

Revenue and valuation

WuXi Biologics grew first-half revenue 18.40 percent to CNY 11.787 billion in 2026.
Adjusted net profit reached CNY 3.306 billion in the first half of 2026.
WuXi Biologics stock last traded at EUR 5.42 at 3:04 a.m. CEST on October 16, 2026 on Tradegate.
The stock had a P/E ratio of 34.45 and a market capitalization of USD 26.2 billion on October 16, 2026.

WuXi Biologics, KYG970081173, Illustration mit AI erstellt.

WuXi Biologics grew first-half revenue 18.40 percent to CNY 11.787 billion in 2026, while adjusted net profit reached CNY 3.306 billion. Moomoo reported the figures from Everbright Securities on October 12, 2026.

Revenue growth remains visible

The first-half revenue figure compares with CNY 9.95 billion in the first half of 2025, according to Moomoo. That 18.40 percent increase was accompanied by a 4.30 percent rise in net profit attributable to shareholders to CNY 2.440 billion. Adjusted net profit grew faster, rising 38.40 percent to CNY 3.306 billion.

The difference between reported and adjusted profit is important for investors because it shows that the operating picture depends on the chosen earnings measure. The company describes a broad biologics platform covering research, development, testing and manufacturing services, including antibodies and other biologic therapies, on its WuXi Biologics investor page.

Valuation and market position

The finance quote for WuXi Biologics showed a P/E ratio of 34.45 and a market capitalization of USD 26.2 billion on October 16, 2026. The same quote listed a 52-week range of USD 3.90 to USD 7.49 and a price of USD 6.36 at the close of the US quotation.

The Hong Kong listing remains the key home-market reference for the company, while the German euro quotation offers a separate access point for investors in Europe. The price frame therefore combines the dated Tradegate level with the latest reported operating figures rather than treating the euro quotation as a substitute for the Hong Kong listing.

What comes next

WuXi Biologics published its first-half 2026 results for the six months ended June 30, 2026. The company also guided to 2026 revenue growth of 20.00 percent to 23.00 percent in constant-currency terms, according to Simply Wall St.

Tradegate price remains the dated marker

The last available euro quotation stood at EUR 5.42 on Tradegate on October 16, 2026 at 3:04 a.m. CEST. The level is dated and should be read alongside the first-half revenue growth, adjusted profit increase and the USD 26.2 billion market capitalization.